Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

ProPhase Labs (PRPH) EBITDA Margin: 2010-2025

Historic EBITDA Margin for ProPhase Labs (PRPH) over the last 16 years, with Sep 2025 value amounting to -774.75%.

  • ProPhase Labs' EBITDA Margin fell 30963.00% to -774.75% in Q3 2025 from the same period last year, while for Sep 2025 it was -820.16%, marking a year-over-year decrease of 517303.00%. This contributed to the annual value of -783.26% for FY2024, which is 73230.00% down from last year.
  • Per ProPhase Labs' latest filing, its EBITDA Margin stood at -774.75% for Q3 2025, which was down 116.13% from -358.46% recorded in Q2 2025.
  • ProPhase Labs' 5-year EBITDA Margin high stood at 277.15% for Q1 2025, and its period low was -2,254.59% during Q4 2024.
  • For the 3-year period, ProPhase Labs' EBITDA Margin averaged around -384.29%, with its median value being -259.13% (2024).
  • Per our database at Business Quant, ProPhase Labs' EBITDA Margin slumped by 238,385bps in 2024 and then skyrocketed by 53,627bps in 2025.
  • Over the past 5 years, ProPhase Labs' EBITDA Margin (Quarterly) stood at 23.33% in 2021, then crashed by 2,975bps to -6.42% in 2022, then skyrocketed by 13,568bps to 129.26% in 2023, then crashed by 238,385bps to -2,254.59% in 2024, then slumped by 30,963bps to -774.75% in 2025.
  • Its EBITDA Margin stands at -774.75% for Q3 2025, versus -358.46% for Q2 2025 and 277.15% for Q1 2025.